Furthermore, in recent years, drugs with different mechanisms of action, such as memantine, are on the market and the usefulness of administering cholinesterase inhibitors in combination with memantine has been demonstrated in patients with moderate to severe Alzheimer's disease. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.